Vilon is the two-amino-acid peptide Lys-Glu, made by Vladimir Khavinson's group in St. Petersburg as a synthetic thymus-type immunomodulator.
Vilon Prices
7 vendors · 0 with an issuer-verified COA · lowest 10mg from $31.19 · checked
Where to buy Vilon: 7 vendors compared
| Vendor | Price | Actions |
|---|---|---|
| $31.19 | Buy Vilon from Cenexa Labs | |
| $32.0610mg packageChecked today | Buy Vilon from Regenix Peptides | |
| $41.39 | Buy Vilon from MS Peptides | |
| $42.49 | Buy Vilon from Orbitrex Peptides | |
| $45.00 | Buy Vilon from Atomik Labz | |
| $46.7720mg packageChecked today | Buy Vilon from Pure Peptides UK | |
| $71.97 | Buy Vilon from BioLongevity Labs |
Tracked every day
Vilon listing prices, tracked daily
The five cheapest in-stock package prices for Vilon on each collected day, and the vendors that most often held those places.
No collected listings for this compound yet.
Current market data
Vilon Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for Vilon is $31.19 from Cenexa Labs. The median across vendors is $42.49.
- Lowest 10mg cost
- $31.19Cenexa Labs
- Median 10mg cost
- $42.49One normalized offer per vendor
- Lowest package total
- $31.19Cenexa Labs · package size may differ
- Public COA coverage
- 100%7 of 7 vendors
What the market shows
PeptidePrices found 8 in-stock listings from 7 vendors, checked through Oct 8, 2026. The lowest 10mg cost is 27% below the vendor median of $42.49; 3 vendors (43%) fall below that median. 7 of 7 vendors (100%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is Vilon? Research, safety, and status
Vilon is about as small as a peptide gets: one lysine bonded to one glutamic acid.
The developers place it in their "cytogen" family of synthetic short peptides, alongside Epitalon (Ala-Glu-Asp-Gly), Cortagen (Ala-Glu-Asp-Pro) and Livagen. A 2001 explant study reported that each of these stimulated growth of the tissue its parent extract came from. Vilon's tissue was the thymus.
Key research takeaways
Its headline claim is a longer life in mice. The 2000 short report says Vilon "prolonged the lifespan" of female CBA mice. The fuller 2001 paper on female CBA mice treated from six months of age reports more physical activity and fewer lung adenomas with Lys-Glu, and gives the survival gain only to the pineal peptide (Epitalon).
Rat tumor studies report fewer chemically induced bladder and colon tumors with Vilon. All come from authors working with the Khavinson group.
Human data are thin: a Russian report on elderly colorectal cancer patients called "pioneer experience" with "preliminary results," plus lab work on blood cells donated by older people.
Not known: whether a dipeptide this small survives in blood long enough to do anything, its half-life, and whether any lab outside the developer network can reproduce the mouse results.
Vilon at a glance
PeptidePrices safety rating
6/10 · Not FDA-approved
Mechanism
Proposed immunomodulatory dipeptide; cell and animal studies report effects on chromatin, gene expression and thymic and stem-cell markers.
Research areas
Immune-system and aging bioregulator research. Human clinical benefit is not established.
Regulatory / research status
Research / preclinical only
Half-life
Not established in direct human pharmacokinetic studies.
Storage
Lyophilized vial: store at -20°C long-term or 2-8°C short-term, protected from light.
Reported side effects
Human safety data is sparse. The available evidence is mainly preclinical and small Russian studies from one research group, and it does not establish clinical efficacy.
Russian bioregulator; short peptide; limited but clean data. Human evidence is thin and mostly from one research group. Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- Vilon is the two-amino-acid peptide Lys-Glu, made by Vladimir Khavinson's group in St. Petersburg as a synthetic thymus-type immunomodulator.
- Its headline claim is a longer life in mice. The 2000 short report says Vilon "prolonged the lifespan" of female CBA mice. The fuller 2001 paper on female CBA mice treated from six months of age reports more physical activity and fewer lung adenomas with Lys-Glu, and gives the survival gain only to the pineal peptide (Epitalon).
- Rat tumor studies report fewer chemically induced bladder and colon tumors with Vilon. All come from authors working with the Khavinson group.
- Human data are thin: a Russian report on elderly colorectal cancer patients called "pioneer experience" with "preliminary results," plus lab work on blood cells donated by older people.
Selected references
- Natural and synthetic thymic peptides as therapeutics for immune dysfunction · PubMed, 1997
- A synthetic dipeptide vilon (L-Lys-L-Glu) inhibits growth of spontaneous tumors and increases life span of mice · PubMed, 2000
- Peptide regulation of gene expression: a systematic review · PubMed, 2021
- RLS Encyclopedia (rlsnet.ru) site search for "вилон," no drug or supplement entry returned · rlsnet.ru
- ClinicalTrials.gov search for "vilon," no matching trials · clinicaltrials.gov
- Effect of vilon on biological age and lifespan in mice · PubMed, 2000
Related pages